0001493152-21-014928.txt : 20210622 0001493152-21-014928.hdr.sgml : 20210622 20210622085704 ACCESSION NUMBER: 0001493152-21-014928 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20210621 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20210622 DATE AS OF CHANGE: 20210622 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intec Pharma Ltd. CENTRAL INDEX KEY: 0001638381 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37521 FILM NUMBER: 211033157 BUSINESS ADDRESS: STREET 1: 12 HARTOM STREET STREET 2: HAR HOTZVIM CITY: JERUSALEM STATE: L3 ZIP: 777512 BUSINESS PHONE: 97225864657 MAIL ADDRESS: STREET 1: 12 HARTOM STREET STREET 2: HAR HOTZVIM CITY: JERUSALEM STATE: L3 ZIP: 777512 8-K 1 form8-k.htm
0001638381 false 0001638381 2021-06-21 2021-06-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

June 21, 2021

 

INTEC PHARMA LTD.

(Exact name of registrant as specified in its charter)

 

Israel   001-37521   N/A
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

12 Hartom St.

Har Hotzvim

   
Jerusalem, Israel   9777512
(Address of principal executive offices)   (Zip Code)
 
+ 972-2-586-4657

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Ordinary Shares, no, par value   NTEC   Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 
 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On June 21, 2021, Intec Pharma Ltd. (the “Company” or “Intec Israel”) held a special meeting of shareholders (the “Special Meeting”) to consider seven proposals related to the Company’s merger with Decoy Biosystems, Inc., a Delaware corporation (“Decoy”), in connection with the Agreement and Plan of Merger and Reorganization dated March 15, 2021 (the “Merger Agreement”) among the Company, Intec Parent, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Intec Parent”), Dillon Merger Subsidiary Inc., a Delaware corporation (“Merger Sub”), Domestication Merger Sub, Ltd., an Israeli company and a wholly-owned subsidiary of Intec Parent (“Domestication Merger Sub”), and Decoy. Each of the Company’s proposals was approved by the requisite vote of the Company’s shareholders as described below.

 

At the close of business on May 20, 2021, the record date for the Special Meeting, there were 4,821,971 ordinary shares of the Company outstanding. The holders of a total of 2,024,212 ordinary shares of the Company were represented at the Special Meeting in person or by proxy, representing approximately 42% of the Company’s ordinary shares entitled to vote at the Special Meeting, which total constituted a quorum for the Special Meeting in accordance with the Company’s bylaws.

 

Set forth below are the matters acted upon by the Company’s shareholders at the Special Meeting and the final voting results on each such matter. Each proposal required approval by holders of a majority of shares of the Company present and entitled to vote a meeting at which a quorum is present. For more information on these proposals, please refer to the Company’s joint proxy statement/prospectus for the Special Meeting, filed with the Securities and Exchange Commission on May 14, 2021.

 

1. Approval of the merger of Merger Sub with and into Decoy, the Merger Agreement and the transactions contemplated thereunder:

 

For     Against     Abstain     Broker Non-Votes
  768,706       14,460       826     1,240,220

 

2. Approval of the domestication of the Company from Israel to the State of Delaware by Domestication Merger Sub merging with and into the Company, the Merger Agreement and certain matters related thereto, including Intec Parent’s amended and restated certificate of incorporation:

 

For     Against     Abstain     Broker Non-Votes
  770,015       13,409       568     1,240,220

 

3. Approval to grant discretionary authority to the board of directors of the Company to amend the articles of association of the Company to effect a reverse stock split of Intec Israel ordinary shares at a ratio within the range between 1-for-2 and 1-for-4 to be effective at the ratio and on a date to be determined by the board of directors of Intec Israel in its sole discretion, prior to the effectiveness of the Domestication Merger.

 

For     Against     Abstain     Broker Non-Votes
  1,923,825       92,405       7,892     0

 

4. Approval to elect Michael J. Newman, Ph.D., Jeffrey A. Meckler, Anthony J. Maddaluna, Hila Karah, Dr. Roger J. Pomerantz, William B. Hayes, Hoonmo Lee and Brian O’Callaghan to serve staggered terms until the first, second and third annual general meeting:

 

Nominee   For     Against     Abstain     Broker
Non-Votes
Michael J. Newmann, Ph.D.     763,139       13,419       7,434     1,240,220
Jeffrey A. Meckler     760,090       15,426       8,476     1,240,220
Anthony J. Maddaluna     763,460       11,886       8,646     1,240,220
Hila Karah     756,240       15,209       12,543     1,240,220
Dr. Roger J. Pomerantz     764,689       10,597       8,706     1,240,220
William B. Hayes     754,043       15,724       14,225     1,240,220
Hoonmo Lee     750,130       20,374       13,488     1,240,220
Brian O’Callaghan     759,929       10,441       13,622     1,240,220

 

 
 

 

5. Approval and adoption of the Intec Parent Option Plan:

 

For     Against     Abstain     Broker Non-Votes
  749,039       21,961       12,993     1,240,220

 

6. Approval of the issuance of such number of Company ordinary shares or Intec Parent common stock in a closing financing as would yield aggregate gross proceeds to the Company or Intec Parent, as applicable, such that the combined net cash of Intec Parent will be not less than $30 million and not more than $50 million:

 

For     Against     Abstain     Broker Non-Votes
  743,435       28,129       12,429     1,240,220

 

7. Approval to adjourn the meeting.

 

For     Against     Abstain     Broker Non-Votes
  2,006,463       10,759       6,990     0

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: June 22, 2021

 

  INTEC PHARMA LTD.
   
  By:  /s/ Nir Sassi
    Nir Sassi
    Chief Financial Officer

 

3

EX-101.SCH 2 ntec-20210621.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 ntec-20210621_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 ntec-20210621_pre.xml XBRL PRESENTATION FILE XML 5 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001638381 2021-06-21 2021-06-21 iso4217:USD shares iso4217:USD shares 0001638381 false 8-K 2021-06-21 INTEC PHARMA LTD. L3 001-37521 12 Hartom St. Har Hotzvim Jerusalem IL 9777512 972 -2-586-4657 true false false false Ordinary Shares, no, par value NTEC NASDAQ true true XML 6 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Jun. 21, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 21, 2021
Entity File Number 001-37521
Entity Registrant Name INTEC PHARMA LTD.
Entity Central Index Key 0001638381
Entity Incorporation, State or Country Code L3
Entity Address, Address Line One 12 Hartom St.
Entity Address, Address Line Two Har Hotzvim
Entity Address, City or Town Jerusalem
Entity Address, Country IL
Entity Address, Postal Zip Code 9777512
City Area Code 972
Local Phone Number -2-586-4657
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Ordinary Shares, no, par value
Trading Symbol NTEC
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://intecpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ntec-20210621.xsd ntec-20210621_lab.xml ntec-20210621_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "ntec-20210621_lab.xml" ] }, "presentationLink": { "local": [ "ntec-20210621_pre.xml" ] }, "schema": { "local": [ "ntec-20210621.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "NTEC", "nsuri": "http://intecpharma.com/20210621", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-06-21to2021-06-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://intecpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2021-06-21to2021-06-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://intecpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 14 0001493152-21-014928-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-014928-xbrl.zip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